ARTICLE | Clinical News
OvaRex: Phase II
March 12, 2001 8:00 AM UTC
ALRXF reported that treatment with OvaRex induced anti-CA125 antibodies in 4 patients and anti-mouse antibodies in 12 of 13 patients with advanced, recurrent ovarian cancer. A total of 6 patients surv...